Best screening tests for osteoporosis risk after menopause in 2026

For osteoporosis risk screening after menopause in 2026, central DXA is the standard bone-density test when screening is indicated. FRAX estimates fracture risk, while spine imaging and blood tests answer different questions rather than replace DXA.

Why this matters

Osteoporosis weakens bones and often causes no symptoms before a fracture. However, menopause alone does not mean you have osteoporosis or need every available test.

The US Preventive Services Task Force recommends screening women aged 65 years and older. For younger postmenopausal women, clinicians first assess risk factors and use a clinical risk tool when appropriate.

Alpha Hormones® emphasizes individualized hormone care, testing when appropriate, and ongoing follow-up. Learn about the practice’s approach on its About Us page.

What makes a useful osteoporosis screening test?

For your 2026 discussion, judge each option by the question it answers:

• Purpose: Does it measure density, estimate risk, or investigate another condition?
• Clinical fit: Does your age, history, or medication use justify it?
• Decision value: Will the result change your care?
• Limitations: What can a reassuring result miss?
• Follow-up: Who will explain the findings and next steps?

Screening options at a glance

These options serve different purposes. The order below reflects their role in routine screening, not a recommendation to complete every test.

1. Central DXA: primary bone-density screening

Central DXA uses low-dose X-rays to measure bone mineral density, usually at your hip and lower spine. It is the main imaging test used in osteoporosis screening after menopause.

• Best for: Women who meet age-based or risk-based screening criteria.
• Standout feature: Measures bone density at clinically important skeletal sites.
• DXA pros: Supports diagnosis and provides a baseline for later comparison.
• DXA cons: Does not capture every cause of fracture risk; spinal arthritis can complicate interpretation.
• Key limitation: A density result needs your medical history for context.

Your report usually includes a T-score, which compares density with a young-adult reference. A T-score of −2.5 or lower at an accepted site meets a bone-density criterion for osteoporosis.

However, a fracture history can change the diagnosis even without that score. Verdict: Choose central DXA when your clinician recommends screening.

2. FRAX: estimating future fracture probability

FRAX combines clinical risk factors to estimate your 10-year probability of hip fracture and major osteoporotic fracture. Clinicians can use it with or without femoral-neck bone-density results.

• Best for: Adding fracture-risk context to a clinical assessment.
• Standout feature: Connects several risk factors in one probability estimate.
• FRAX pros: Adds information beyond a bone-density result alone.
• FRAX cons: Does not measure bone density or fully capture falls and recent fractures.
• Key limitation: Incorrect inputs can produce a misleading estimate.

For example, a clinician should review how previous fractures and medication exposure affect interpretation. Therefore, FRAX is not a self-diagnosis tool.

Verdict: Use FRAX as a clinical decision aid, not a DXA replacement.

3. Vertebral fracture assessment: checking for spinal fractures

Vertebral fracture assessment, or VFA, uses a DXA machine to look for vertebral compression fractures. These fractures involve bones in your spine and sometimes occur without a recognized injury.

• Best for: Selected patients with findings such as height loss or suspected vertebral fracture.
• Standout feature: Checks vertebral shape rather than density alone.
• VFA pros: Can identify previously unrecognized spinal fractures.
• VFA cons: Does not replace diagnostic imaging for every symptom or unclear finding.
• Key limitation: Not everyone needs it alongside routine DXA.

New back pain needs clinical assessment, especially after a fall or minor strain. In that situation, your clinician determines which imaging fits the concern.

Verdict: Hold unless your history, examination, or DXA findings support it.

4. Targeted blood tests: investigating contributing conditions

Blood tests do not diagnose osteoporosis by measuring bone density. Instead, selected tests help clinicians investigate conditions that contribute to bone loss.

• Best for: Investigating low density, fractures, or a suspected underlying condition.
• Standout feature: Examines possible causes that imaging cannot explain.
• Blood-test pros: Can inform treatment safety and further investigation.
• Blood-test cons: Broad panels can create unnecessary findings and follow-up.
• Key limitation: Normal results do not rule out osteoporosis.

Depending on your history, testing can include calcium, kidney function, and vitamin D. Thyroid or other testing belongs in the plan when there is a clinical reason.

Verdict: Choose targeted tests for a defined question, not a blanket hormone panel.

5. Heel ultrasound: limited peripheral assessment

Heel ultrasound assesses bone properties using sound waves. However, its results are not interchangeable with central DXA measurements.

• Best for: Selected risk-assessment settings when central DXA access is limited.
• Standout feature: Uses no ionizing radiation.
• Heel-ultrasound pros: Offers a portable assessment option.
• Heel-ultrasound cons: Cannot apply central DXA diagnostic thresholds or replace standard treatment monitoring.
• Key limitation: A reassuring result does not settle whether you need DXA.

If you receive a heel-screening result, bring it to your clinician. Verdict: Skip it as a substitute for indicated central DXA.

How to choose your next step

A practical 2026 plan starts with your history, not a shopping list of tests:

1. Clinical review: Discuss fractures, falls, height loss, medications, and family history.
2. Risk assessment: Consider age and other factors that affect screening decisions.
3. DXA decision: Decide whether central DXA and any additional testing are indicated.

Also, bring previous scans and a current medication list. A fracture after a minor fall can require diagnostic evaluation rather than routine screening.

How the options are ranked

For 2026 care decisions, this order follows each option’s clinical purpose. Central DXA measures density; FRAX estimates risk; additional tests address specific findings.

The reference framework is the USPSTF recommendation, Osteoporosis to Prevent Fractures: Screening. International Society for Clinical Densitometry Adult Official Positions and the Bone Health and Osteoporosis Foundation’s Clinician’s Guide support interpretation and further evaluation.

FAQ

One last thing

A prior low-trauma fracture can matter more than a reassuring density label. For your 2026 appointment, bring details of fractures rather than assuming an old injury is unrelated.

Alpha Hormones® provides individualized hormone care, but hormone treatment does not replace a bone-health assessment. Treatment decisions require your history, clinical findings, and provider judgment.

Related guides

• Can BHRT cause blood clots?
• Is bioidentical hormone replacement therapy FDA-approved?

To discuss your menopause-related concerns with Alpha Hormones®, Book an appointment.